ATLANTA, July 11, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) complied with federal securities laws. On July 8, 2025, RxSight announced select preliminary financial results for the second quarter 2025 and revised full-year 2025 guidance, revealing declines in revenue, Light Delivery Devices sales, and usage of Light Adjustable Lenses. Following this news, the price of the Company’s stock dropped.  If you purchased RxSight s ...

Core Insights - Certara, Inc. is positioned to potentially continue its earnings-beat streak in the upcoming report, having surpassed earnings estimates by an average of 11.54% in the last two quarters [1][2]. Earnings Performance - In the last reported quarter, Certara achieved earnings of $0.14 per share, exceeding the Zacks Consensus Estimate of $0.13 per share, resulting in a surprise of 7.69% [2]. - In the previous quarter, the company was expected to post earnings of $0.13 per share but delivered $0.15 per share, leading to a surprise of 15.38% [2]. Earnings Estimates and Predictions - Recent estimates for Certara have been trending upward, with a positive Earnings ESP of +2.44%, indicating increased analyst optimism regarding the company's earnings prospects [5][8]. - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat, with historical data showing that stocks with this combination beat estimates nearly 70% of the time [6][8]. Earnings ESP Explanation - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions, which may be more accurate [7]. - A negative Earnings ESP can reduce the predictive power of the metric, but it does not necessarily indicate an earnings miss [9]. Importance of Earnings ESP - Many companies beat consensus EPS estimates, but this is not the sole reason for share price gains; thus, checking a company's Earnings ESP before quarterly releases is crucial for investment decisions [10].

Demographic Shift and Healthcare Demand - The world is experiencing a significant demographic shift with populations aging rapidly, where individuals aged 60 and older outnumber children under five for the first time in 2020, projected to exceed 2 billion by 2050 [2] - The U.S. population aged 65 and older is expected to nearly double by 2050, with those aged 85 and older projected to triple by 2060 [2] Geriatric Care Market Growth - The global geriatric care services market, valued at $1 trillion in 2022, is expected to more than double by 2033, driven by growth in pharmaceuticals, medical devices, long-term and home-based care, and digital health solutions [3] Healthcare Challenges in the U.S. - Mortality rates among seniors have increased by 4.5% annually, with a 50% rise for those aged 85 and older; Alzheimer's and dementia-related deaths are up 40% [4] - Hospital utilization is surging, with admissions rising by 25%, average stay lengthening, readmissions increasing by 20%, and emergency visits soaring by 40% [4] Pharmaceutical and Device Companies' Response - Pharmaceutical firms like Roche and Novo Nordisk are focusing on high-demand areas, while device makers such as Edwards Lifesciences and Stryker are advancing tools for chronic disease management [5] Digital Health Innovations - Digital health is transforming elder care with AI-powered diagnostics, remote monitoring, and wearables, leading to better outcomes and new revenue models [6] - The demand for home care is rising as more seniors choose to age at home, although a projected shortage of 2.3 million long-term care workers by 2030 poses challenges [6] Financial Trends in Senior Care - U.S. senior care spending exceeded $1 trillion in 2022 and could double by 2040, emphasizing the need for value-based models and efficient chronic disease management [7] Roche's Strategic Initiatives - Roche is advancing Alzheimer's diagnostics with the Elecsys Amyloid Plasma Panel, showing 91% sensitivity and 96.2% negative predictive value, and has announced a $50 billion investment in U.S. operations over five years [8][9] Novo Nordisk's Regulatory Wins - Novo Nordisk's Ozempic received FDA approval for reducing kidney disease progression and cardiovascular death in adults with Type 2 diabetes, and the company is investing €2.34 billion to upgrade its production facility in Italy [10][11] Edwards Lifesciences' Innovations - Edwards Lifesciences is focusing on aortic stenosis care, with new data showing early treatment reduces costs and improves outcomes; TAVR sales reached $1.05 billion in Q1 2025 [12][13] Stryker's Market Penetration - Stryker is making strategic investments in senior healthcare, enhancing capabilities in minimally invasive neurosurgery through acquisitions, and offering products designed to improve outcomes for elderly patients [14][15]

 Toronto, Ontario – TheNewswire - July 11, 2025 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”), (TSXV:VPT) is pleased to announce that it has signed a non-binding term sheet with Lishman Global Inc. outlining the exclusive , non-transferable license of Ventripoint technology for use within Lishman’s echocardiography image platform in the People’s Republic of China including the Special Administrative Regions of Hong Kong and Macao (the “Territory”).  Previously, Lishman’s Chinese subsi ...

Core Viewpoint - Johnson Fistel, PLLP is investigating RxSight, Inc. for potential violations of federal securities laws related to misleading statements and undisclosed material information to investors [1][3]. Company Overview - RxSight, Inc. is facing scrutiny regarding its business outlook and product adoption trends, particularly after reporting significant declines in Light Delivery Device (LDD) sales and total revenue for Q2 2025 [3]. Financial Performance - On July 9, 2025, RxSight released preliminary financial results indicating notable declines in LDD sales and usage of its light adjustable intraocular lenses (LALs) [3]. - The company revised its full-year 2025 revenue guidance downward by approximately $42.5 million at the midpoint, attributing this to "adoption challenges over the last few quarters" [3]. Legal Investigation - The investigation by Johnson Fistel focuses on whether RxSight misled investors about its financial performance and future prospects [3]. - Investors who purchased RxSight securities and incurred losses may be eligible to participate in the investigation [2]. Whistleblower Information - Individuals with nonpublic information about RxSight are encouraged to assist with the investigation or explore options under the SEC Whistleblower Program, which may offer rewards of up to 30% of any successful enforcement action [4]. Law Firm Background - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights and securities fraud, with a strong track record in securing recoveries for clients [5][6].

Core Insights - The integration of generative AI and agentic AI in medical devices is transforming clinical workflows and patient care, with generative AI focusing on content creation and design optimization, while agentic AI enables autonomous decision-making based on real-time data [1][3] Group 1: AI Integration in Medical Devices - Generative AI is used to create synthetic medical images for training diagnostic tools, enhancing datasets [1] - Agentic AI supports predictive maintenance in medical equipment, reducing downtime through fault detection and automated service scheduling [3] - AI-powered tools like Nuance Communications's Dragon Ambient eXperience improve clinical documentation by transcribing doctor-patient conversations into structured notes [2] Group 2: Key Factors Driving AI Adoption - There is a rising demand for precision and personalized medicine, with AI enabling individualized diagnostics and treatments based on patient-specific data [5] - The regulatory environment is favorable, with over 700 AI-enabled devices approved by the FDA, significantly increasing from 2020 [6] Group 3: Medical Device Stocks to Watch - Boston Scientific Corporation (BSX) is investing in AI for improved procedural outcomes, with a projected 2025 sales growth rate of 16.4% and earnings expected to grow by 15.9% [8][7] - Johnson & Johnson (JNJ) employs AI in surgical robotics and digital surgery analytics, with a historical earnings growth rate of 5.5% and projected sales growth of 2.8% for 2025 [11][10] - GE HealthCare Technologies Inc. (GEHC) leads in FDA-cleared AI devices, with a projected sales growth rate of 3.2% for 2025 and a focus on enhancing imaging through AI solutions [13][12]

TORONTO and GLIL YAM, Israel, July 11, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce the filing and effectiveness of a shelf registration statement (the "Shelf Registration") on Form F-3 with the Securities and Exchange Commission ("SEC").The Shelf Registration will allow the Company to offer and sell, from time to time, up to an aggregate of $50 million of its common shares, wa ...

Core Insights - The report titled "North America Cystoscopes Market Outlook to 2033" provides a comprehensive analysis of the cystoscopes market in North America, covering various segments including Flexible Non-Video (Fibre) Cystoscopes, Flexible Video Cystoscopes, and Rigid Non-Video (Fibre) Cystoscopes [2][5]. Market Overview - The report includes annualized market revenues, volume, and average pricing data from 2018 through 2033 for each market segment, offering insights into market trends and forecasts [7]. - It provides detailed market data including value in USD, volume in units, and average prices across significant market segments [2][7]. Market Segmentation - The report segments the market into three main categories: Flexible Non-Video (Fibre) Cystoscopes, Flexible Video Cystoscopes, and Rigid Non-Video (Fibre) Cystoscopes, allowing stakeholders to identify key growth areas [7][8]. - Specific data on the Canadian and Mexican markets is also included, detailing revenue, volume, and average pricing from 2018 to 2033 [8][13]. Strategic Insights - The report aims to empower industry stakeholders to make strategic decisions by providing critical data and analysis necessary for navigating the evolving landscape of the North America Cystoscopes Market [5]. - It highlights the importance of crafting robust business strategies by identifying key market segments anticipated for notable growth in the coming years [7]. Company Profiles - The report includes global corporate-level profiles of significant players in the North America Cystoscopes Market, such as Olympus Corp, KARL STORZ SE & Co KG, and Stryker Corp, among others [11][14]. - Company share and distribution share data specific to the Cystoscopes Market for 2023 is also provided, offering insights into competitive positioning [7][13].

Core Insights - The report titled "North America Ureteroscopes Market Outlook to 2033" provides a comprehensive analysis of the ureteroscopes market in North America, focusing on various segments including Flexible Non-Video (Fibre) Ureteroscopes, Semi Rigid Ureteroscopes, and Flexible Ureteroscopes [1][4]. Market Overview - The report includes detailed data on market value (USD), volume (units), and average prices (USD) for different segments of the ureteroscopes market [1][4]. - It covers annualized market revenues from 2018 to 2033, providing insights into revenue trends and projections [4][5]. Regional Analysis - The report segments the ureteroscopes market by country, specifically analyzing the markets in Canada, Mexico, and the United States [3][4][7]. - For each country, the report provides revenue, volume, and average price data from 2018 to 2033, along with distribution share and company share data for 2023 [4][6][10]. Competitive Landscape - The report profiles key companies operating in the North America ureteroscopes market, including Boston Scientific Corp, KARL STORZ SE & Co KG, and Olympus Corp, among others [8][10]. - It discusses business strategies and market positioning of these companies, identifying key segments poised for growth [4][8]. Strategic Insights - The report outlines market-entry and expansion strategies, as well as competition strategies by identifying market leaders and their positions [4][5]. - It emphasizes the importance of understanding distribution channels and preferred modes of product distribution to capitalize on market opportunities [4].

One of the good things about the healthcare sector is that most medical care isn't optional. This is the foundation behind the sector, but on that foundation sits the growth opportunity that comes with medical advances.Right now one of the best healthcare stocks to look at is medical device giant Medtronic (MDT 0.39%), which is offering a historically high 3.2% dividend yield.Here's why you might want to invest $1,000 in it right now, a sum that will allow you to buy roughly 11 shares. What Medtronic has to ...